Is %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall‐Cell Lung Cancer?
Open Access
- 1 January 2013
- journal article
- research article
- Published by Wiley in The Scientific World Journal
- Vol. 2013 (1) , 910957
Abstract
Purpose. To investigate the impact of the maximum standardized uptake value (SUVmax), size of primary lung lesion, and %ΔSUVmax on outcome (overall survival (OS) and 2‐year disease‐free survival (2‐year DFS)) of patients with advanced nonsmall‐cell lung cancer (NSCLC). Materials and Methods. 86 stage III‐IV NSCLC patients underwent 18 F‐FDGPET/CT, before and after chemotherapy, and were classified into subgroups according to the response criteria of the European Organization for Research and Treatment of Cancer. SUVmax values and tumor size with the best prognostic significance were searched. Correlation between the SUVmax value and the initial response to therapy (best response) and the relationship between %ΔSUVmax and OS were assessed. Results. In patients in PD (20/86), the average pretreatment SUVmax was 11.8 ± 5.23, and the mean size of the primary lesion was 43.35 mm ± 16.63. In SD, PR, and CR patients (66/86), the average pretreatment SUVmax was 12.7 ± 8.05, and the mean size of the primary lesion was 41.6 mm ± 21.15. Correlation was identified only for %ΔSUVmax; patients with PD (ΔSUVmax > +25%) showed a worse OS than patients with ΔSUVmax < +25% (CR, PR, and SD) (P = 0.0235). Conclusions. In stage III‐IV NSCLC, among the assessed factors, only %ΔSUVmax may be considered as a useful prognostic factor.Keywords
This publication has 20 references indexed in Scilit:
- Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantificaRadiology and Oncology, 2013
- Recent advances in non-small cell lung cancer biology and clinical management.2012
- Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non–Small-Cell Lung CarcinomaJournal of Clinical Oncology, 2008
- Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer ResectionJournal of Clinical Oncology, 2004
- Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose UseJournal of Clinical Oncology, 2003
- Anatomy of SUVNuclear Medicine and Biology, 2000
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendationsEuropean Journal of Cancer, 1999
- Reproducibility of metabolic measurements in malignant tumors using FDG PET.1999